Trade Name | Active Pharmaceutical Ingredient | Formulation | Average Diameter, nm | Route of Administration | Approval Year |
---|---|---|---|---|---|
Doxil | Doxorubicin | Liposome | 85 | Intravenous | 1995 |
DaunoXome | Daunorubicin | Liposome | 45 | Intravenous | 1996 |
AmBisome | Amphotericin B | Liposome | 60–70 | Intravenous | 1997 |
Visudyne | Verteporfin | Liposome | 18–104 | Intravenous | 2000 |
Marqibo | Vincristine sulfate | Liposome | 100 | Intravenous | 2012 |
Onivyde | Irinotecan HCL | Liposome | 110 | Intravenous | 2015 |
Vyxeos | Daunorubicin/cytarabine | Liposome | 100 | Intravenous | 2017 |
Abraxane | Paclitaxel | Nanoparticle | 130 | Intravenous | 2005 |
Somatuline | Lanreotide acetate | Nanotube | 24 | Subcutaneous | 2007 |
Abelcet | Amphotericin B | Lipid complex | 1600–11,100 | Intravenous | 1995 |
Amphotec | Amphotericin B | Lipid complex | 150 | Intravenous | 1996 |
Onpattro | Patisiran | Lipid complex | <100 | Intravenous | 2018 |
Note that Abelcet is included in an FDA NP product list (Bobo et al., 2016; Zheng et al., 2017) but has been reported to have an average diameter of >1000 nm (Clark et al., 1991; Johnson et al., 1998).